Holen Sie sich die Stockscreener-App
125.01
1.58%
1.94
Handel nachbörslich:
125.00
-0.01
-0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$123.07
Offen:
$123
24-Stunden-Volumen:
822.83K
Relative Volume:
0.94
Marktkapitalisierung:
$11.92B
Einnahmen:
$1.50B
Nettoeinkommen (Verlust:
$47.30M
KGV:
-15.97
EPS:
-7.83
Netto-Cashflow:
$-527.92M
1W Leistung:
-3.99%
1M Leistung:
+3.83%
6M Leistung:
-6.47%
1J Leistung:
+60.25%
1-Tages-Spanne:
$121.18
$125.25
1-Wochen-Bereich:
$121.01
$130.85
52-Wochen-Spanne:
$75.85
$173.25
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Allspring Global Investments Holdings LLC Sells 21,269 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Emerald Advisers LLC Has $1.04 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Gladstone Institutional Advisory LLC Acquires 26,900 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Interesting SRPT Put And Call Options For December 13th - Nasdaq
Pinnacle Associates Ltd. Has $11.48 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics (SRPT) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by abrdn plc - MarketBeat
China Universal Asset Management Co. Ltd. Has $2.29 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Sarepta’s Recent Elevidys Presentations Leave Duchenne Community Wanting - BioSpace
Sarepta Therapeutics, Inc. (SRPT): An Unstoppable Stock That Could Make You Richer - Insider Monkey
8 Unstoppable Stocks That Could Make You Richer - Insider Monkey
Assenagon Asset Management S.A. Has $43.72 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics' SWOT analysis: stock poised for growth as Elevidys expands DMD market reach - Investing.com
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results - BioSpace
Q2 EPS Estimate for Sarepta Therapeutics Lifted by Analyst - MarketBeat
Zacks Research Issues Positive Forecast for SRPT Earnings - MarketBeat
Exploring High Growth Tech Stocks In United States October 2024 - Simply Wall St
Sarepta a new buy at Jefferies on muscular dystrophy franchise, pipeline - MSN
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights - Benzinga
Royal Bank of Canada Reaffirms Outperform Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Sarepta stock a 'buy' as Jefferies forecasts $4B peak sales from DMD gene therapy - Investing.com Canada
Sarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from Analysts at Jefferies Financial Group - MarketBeat
Unveiling 15 Analyst Insights On Sarepta Therapeutics - Benzinga
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment? - Simply Wall St
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $183.89 Consensus Price Target from Analysts - MarketBeat
Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey
Sarepta upgraded at Oppenheimer on potential Elevidys label expansion - MSN
Muscular Dystrophy Treatment Market Transformative Trends: - openPR
mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way - GlobeNewswire Inc.
Sarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Needham & Company LLC - MarketBeat
Barclays maintains Overweight rating on Sarepta Therapeutics shares By Investing.com - Investing.com UK
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5%Should You Buy? - MarketBeat
Sarepta Therapeutics (NASDAQ:SRPT) Given "Outperform" Rating at Raymond James - MarketBeat
Gene Therapy For Rare Disease Market Report: Growth Forecast - openPR
Limb Girdle Muscular Dystrophy Market 2024-2031Jubilant Cadista Pharmaceuticals Inc., Sarepta Therapeutics, Inc. - openPR
Sarepta shares hold as BMO maintains Outperform rating on Elevidy data - Investing.com UK
Connective Portfolio Management LLC Takes $1.62 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial - Nature.com
Sei Investments Co. Lowers Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc - Yahoo Finance
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics - Benzinga
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $182.00 at Royal Bank of Canada - MarketBeat
Clearbridge Investments LLC Boosts Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Six biotechs driving progress in Duchenne muscular dystrophy - Labiotech.eu
Teachers Retirement System of The State of Kentucky Purchases New Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):